P234 Implementation of an ambulatory pathway for the initiation of home non-invasive ventilation: A pilot project

P234 Table 1Characteristics and outcomes in ambulatory home NIV pathwayCharacteristic Frequency Paired samples test Age, years (mean, SD) 62 (16) n/a Gender, male (number,%) 31 (44) n/a Diagnosis (number,%) Neuromuscular disease 29 (41) n/a OHS ± OSA 24 (34) n/a COPD 20 (29) n/a CWD 6 (9) n/a CSA 3 (4) n/a Ambulatory setup method (number,%) 63 (90) n/a Offsite setup method (number,%) 7 (10) n/a Change in pCO2, kPa (median, IQR) -2 24 (2 93) p = 0 007 Change in mean overnight SpO2,% (median, IQR) +2 00 (3 03) p = 0 004 Mean NIV use when used, hours/night (mean, SD) 5 21 (3 98) n/a NIV compliance (number,%) 42/68 (62) n/a Legend: OHS = obesity hypoventilation syndrome;OSA = obstructive sleep apnoea;COPD = chronic obstructive pulmonary disease;CWD = chest wall disease;CSA = central sleep apnoea;n/a = not applicable ConclusionsAn ambulatory model for initiation of home NIV appears to be as effective in achieving compliance as inpatient admission, while carrying health economic benefits Ambulatory treatment pathways enabled us to deliver service continuity during the COVID-19 pandemic ReferencesMandal S, Arbane G, Murphy P et al Medium-term cost-effectiveness of an automated non-invasive ventilation outpatient set-up versus a standard fixed level non-invasive ventilation inpatient set-up in obese patients with chronic respiratory failure: a protocol description BMJ Open 2015;5;e007082 Ward K, Chakrabarti B, Ashcroft H et al Compliance with non-invasive ventilation (NIV) at 90 days may be associated with use of NIV in the first 2 weeks: investigation of telemonitoring data AJRCCM 2018;197;A1463